EDEN RESEARCH PLC (EDEN) — Preliminary results for the fifteen months ended 31 March 2026

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the EDEN RESEARCH PLC investor presentation. During this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the q and a tab situated on the right hand corner of your screen. Please just simply type in your questions and press send. Before we begin, I'd like to submit the following poll. And now I'd like hand you over to Sean Smith, CEO. Good morning, sir. Good morning, and thanks, Charlie. And thank you everyone for joining us this morning for our 2026 preliminary results. Without further ado, we'll leap right in. And bear with us, this is a a new presentation format, so there are some elements of this that'll be new and informative, we hope, in addition to the preliminary results. So moving right along is a very high level summary of EDEN for those that are new to the story in particular. EDEN is unique in that we are the only aim listed company focused on biopesticides for sustainable agriculture. We are not unique across the European landscape nor are we we globally. But certainly from an end context, we we are unique in that regard. For us, just at very high level, currently, we have 33 countries in which our products are approved, and you will come to appreciate, I hope through this presentation that regulatory approvals are the be all end all for for us. Without regulatory authorization for a given product in a given country for a specific, and I mean, specific use, we are not able to sell our products without that clearance. And so as we grow this number from one not too many years ago to 33 today, we've been effectively investing in the increase of our addressable market. Today, there are over a 100 crop uses approved. A number of years ago when our first pro...